Particularly, increased levels of IL-1β, IL-6 and TNF-α in ALS patients compared to controls or patients with other neuropathies have been reported [12,38,39,40], suggesting that the modulation of these inflammatory mediators may ameliorate the course of the disease. The gene discussed is IL6; the disease is amyotrophic lateral sclerosis.